Indeed, mutations in RAC1 enhanced melanoma disease progression: RAC1 P29S analysis in a cohort of 814 primary cutaneous melanomas, with known BRAF and NRAS mutation status, revealed an association with increased tumor thickness, increased mitotic rate, ulceration, and presence of lymph node metastases at the time of diagnosis (Mar et al., 2014). The gene discussed is NRAS; the disease is cutaneous melanoma.